Navigation Links
Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Date:9/21/2011

BROOMFIELD, Colo., Sept. 21, 2011 /PRNewswire/ -- Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).

While the precise cause of migraines is not fully understood, changes in vascular tone and inflammatory processes appear to be key contributing factors.  Prostaglandins are naturally existing molecules that are integral components of both vascular and inflammatory reactions in the central and peripheral nervous systems.   There is evidence to demonstrate that prostaglandin E2 (PGE2) binding to the EP4 receptor causes dilation of small blood vessels in the brain, while leaving coronary and pulmonary arteries unaffected, and can stimulate a variety of inflammatory mechanisms.  AP-1531 is a potent and selective EP4 receptor antagonist that specifically targets PGE2-EP4 binding which may treat migraines. AP-1531 has shown promising results  in several disease models of migraine and acute pain and inflammation.  

"We are extremely pleased with the data from six Phase I studies on AP-1531 and are confident this approach will yield positive results as we initiate a Phase 2 study in migraine patients in 2012," said Steve Orndorff, President and CEO of Ariel Pharmaceuticals.  "Given that the current standard of care for moderate to severe migraines can take up to 90 minutes to provide relief and works temporarily or not at all in many patients, in addition to having potentially serious side effects, we're committed to developing a safer and more efficacious alternative that will provide better quality care to patients.  We believe AP-1531 will validate our business model of in-licensing clinic-ready dru
'/>"/>

SOURCE Ariel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ariel Ways GovBuys Awarded VA Contract
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
(Date:9/20/2014)... have advised their patients against drinking coffee and wine. Dr. ... advice and changing his stance after considering two recent studies ... health. “There’s good news and great news,” says Dr. Wells, ... against gum disease, and red wine can help fight cavities!” ... September 2014 issue of Boston University School of Medicine ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Earlier this ... their customers may have had their credit card information pilfered ... year, spawning a slew of headline articles like this ... weren’t the only eye opening numbers. , “Most people ... stolen, almost like it’s a way to score a game,” ...
(Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
(Date:9/20/2014)... FL (PRWEB) September 20, 2014 The ... get the balanced and active play they need. An ... Branches Center - Lakeview Campus was transformed into a ... help of 150+ volunteers from Branches (@BranchesFL), ESPN (@TeamESPN), ... , KaBOOM! believes a playground is more than ...
(Date:9/19/2014)... Are you tired of having to repeatedly reach ... or sinus congestion? Fortunately, an inventor from Newmanstown, Pa., ... conceived of Nose Pal to avoid the worry and ... Since it prevents nasal drip and the constant need ... cooking or working closely with others. What's more, you ...
Breaking Medicine News(10 mins):Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... A potent new inhibitor of HIV, derived from bananas, may ... of HIV, according to a University of Michigan Medical School ... interest in lectins, naturally occurring chemicals in plants, because of ... to a variety of infections. In laboratory tests, ...
... Saunders as chief executive officer and appointed him to the Board of Directors, effective immediately. , ... , , ... ... Current Chairman and CEO Gerald M. Ostrov ...
... Third-Generation, Family-Owned Company Joins March for Babies (R) , ... , , ... ... WHITE ...
... Grand Rapids ... ... the increasing demand for non-surgical aesthetic procedures, FDA’s recent clearance of an ultrasound device in ... to one of the first of these Ulthera™ Systems in the nation. , , , ...
... ... insurance companies to cover Sedation Dentistry for Georgia Dental Patients with severe anxiety and other ... just found out about the law so the general public knows little or nothing about ... (Vocus) ...
... ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to ... ... , , ... ...
Cached Medicine News:Health News:University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection 2Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 2Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 3Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 4Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 2Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 3Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 4Health News:Medical Ultrasound Now Used in New, Non-surgical Cosmetic Procedure 2Health News:Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5
... Until now, laborious custom fabrication was required ... was limited and modifications in response to ... cumbersome.,The GunSlinger evolved from two years of ... teaching hospital. This orthosis can be quickly ...
... abduction of shoulder, elbow, wrist, and hand. ... is supported by the opposite shoulder. Abduction ... Foam arm support attaches to pillow wedge ... be attached anywhere along length of arm. ...
... is designed for the management of ... fractures. The lightweight anatomical design achieves ... for optimal control of humeral segments ... the shoulder and elbow joints. It ...
Provides secure fracture immobilization while allowing for full range of motion at shoulder and elbow...
Medicine Products: